Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
To contribute published user compound and/or population files, upload your files here: Upload Model Files
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Capmatinib. Note: The fuGut in the inhibitor file is set as user input to 1. A minimal PBPK model with VSAC is used. Link to the publication with further details: http://doi.org/10.1002/psp4.12672
The Ceftazidime file is set as IV infusion of 1g over 3 minutes (0.05 h), thus the user is advised to ensure that after oral dosing an fa of 1 (CV=0%), ka of 2 h-1 (CV=30%) and a lag time of 1.5 h (30%) is used as stated in the Supplement Material Table S1 of the publication (PMID: 38675135). The Ceftazidime file has been evaluated in a Pregnant Population.
Simcyp developed Paclitaxel compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.
The RES-Simvastatin lactone and RES-Simvastatin acid models within the Simcyp Compound Repository have been developed as substrates of CYP3A4, CYP2C8, BCRP (simvastatin lactone), CES1 (simvastatin lactone) and OATP1B1 (simvastatin acid). Additionally, the models account for the interconversion between the lactone and acid forms in the acidic environment of the stomach. Note: Before running a simulation, modify the population to account for gastric luminalmetabolism. To do this, follow these steps:
This document provides:
|
17 |